BHV-1300
Pipeline Category
Pharmaceutical
Short Description / Indication
Molecular Degraders of Extracellular Proteins (“MoDE™”) are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal/lysosomal pathway---a novel, competitive platform with a differentiated profile relative to FcRN inhibitors. Specifically, high circulating levels of antibodies (monoclonal or polyclonal gammopathy) drive conditions such as myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, and many other diseases.
Areas of Focus
Discovery Platform
Inflammatory
Therapeutics
Licensees
Company Name | Company Website URL |
---|---|
Biohaven | https://www.biohaven.com/ |
Pharmaceutical Status